NCT05751486View on ClinicalTrials.gov

A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 21, 2022

Primary Completion Date

December 30, 2023

Study Completion Date

December 30, 2025

Conditions
Advanced Nasopharyngeal Carcinoma
Interventions
BIOLOGICAL

Toripalimab injection(subcutaneous)/JS001sc

JS001sc Q3W combination with gemcitabine and cisplatin.

BIOLOGICAL

Toripalimab injection(subcutaneous)/JS001sc

JS001sc long period combination with gemcitabine and cisplatin.

BIOLOGICAL

Toripalimab /JS001

JS001 IV (if applicable) .

BIOLOGICAL

Toripalimab injection(subcutaneous)/JS001sc

Additional cohort (if applicable)

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER